CureVac’s (CVAC) “Neutral” Rating Reiterated at UBS Group
UBS Group reaffirmed their neutral rating on shares of CureVac (NASDAQ:CVAC – Free Report) in a research report report published on Thursday,Benzinga reports. The firm currently has a $5.50 price objective on the stock, down from their previous price objective of $12.00. CVAC has been the subject of a number of other reports. Jefferies Financial […]
UBS Group reaffirmed their neutral rating on shares of CureVac (NASDAQ:CVAC – Free Report) in a research report report published on Thursday,Benzinga reports. The firm currently has a $5.50 price objective on the stock, down from their previous price objective of $12.00. CVAC has been the subject of a number of other reports. Jefferies Financial […]
